Aohua Pharmaceutical: Using 180 million yuan of idle funds to purchase financial products.

Kuihua Pharmaceutical announced that, after being reviewed and approved at the 20th meeting of the Fifth Board of Directors and the 2025 Annual Shareholders' Meeting, it has decided to use up to 2 billion yuan of idle funds for cash management, with a term of 12 months and a rolling limit. Recently, the company used 180 million yuan to purchase a financial product from the Harbin Xiangfang Branch of Bank of China, with an interest start date of June 25, 2026, and a maturity date of January 11, 2027, with an expected annualized return of 2.40%. As of the date of the announcement, the amount of funds not yet matured in the company's cash management is 1.48 billion yuan.